Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications Nervous system neoplasms
- Focus Adverse reactions
- 18 Mar 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2017 Planned number of patients changed from 40 to 55.